Neogen Voluntarily Recalls Hycoat Product
Neogen is voluntarily recalling all lots within expiry of Neogen Vet Hycoat Hyaluronate Sodium Sterile Solution, for use in dogs, cats, and horses, to the veterinarian level. Neogen distributes this product, which is manufactured by a third-party supplier. This recall has been initiated due to microbial contamination in certain lots of 10 mL/50 mg product vials. Neogen received a number of reports of adverse events in horses following intraarticular injections of this product, which is inconsistent with its labeled, intended use. To date, Neogen has not received reports of adverse events when used in a manner consistent with the labeled use. While the company's investigation into this issue is ongoing, out of an abundance of caution the 2mL/20mg product vials are also being recalled. The company is proactively working with the FDA on this matter. This product is labeled as a sterile solution, but due to microbial contamination of certain lots, the recalled lots should no longer be considered sterile. The risk is particularly acute when used as an intraarticular injection, inconsistent with its labeled, intended use. No other Neogen products are affected by this field action.
Trade with 70% Backtested Accuracy
Analyst Views on NEOG
About NEOG
About the author

- Oversold Signal: Neogen Corp (Ticker: NEOG) saw its RSI drop to 28.7 during Monday's trading, indicating the stock has entered oversold territory, suggesting that recent heavy selling may be exhausting, prompting investors to look for buying opportunities.
- Price Fluctuation: NEOG shares hit a low of $9.145, with the current trading price at $9.43, fluctuating between a 52-week low of $3.8701 and a high of $11.425, reflecting changing market sentiment towards the stock.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 36.7, NEOG's 28.7 RSI indicates relative weakness, potentially attracting investors looking for a rebound.
- Investor Sentiment: Despite the current price slump, the oversold signal may lead investors to reassess NEOG's value, especially after significant price declines, which could create buying opportunities.

- Stock Performance: ZOETIS shares have decreased by 1.4% following a recent deal announcement.
- Acquisition Details: The company is set to acquire Neogen's animal genomics unit for a total of $160 million.
- Product Recall: Neogen Corporation has initiated a voluntary recall of all unexpired lots of its HYCOAT Hyaluronate Sodium Sterile Solution due to identified microbial contamination in certain batches, impacting its use for topical wound management in dogs, cats, and horses.
- Adverse Event Reports: The company received several adverse event reports following intra-articular injections in horses, a use inconsistent with the product's labeling, although no adverse events were reported when used as directed, highlighting the risks associated with improper use.
- Infection Risk Warning: Neogen warned that affected products should no longer be considered sterile, posing an infection risk particularly if injected into joints or used topically in surgical wounds, burns, ulcers, and autograft procedures.
- Stock Price Reaction: According to Benzinga Pro data, NEOG stock fell 2.80% to $10.06 in the last check on Thursday, reflecting the market's negative response to the recall event.
- Product Recall: Neogen Corporation is voluntarily recalling all lots of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution due to microbial contamination in certain 10 mL/50 mg vials, which poses a risk of infection in animals and could damage the company's reputation.
- Adverse Event Reports: The company has received multiple reports of adverse events in horses following intraarticular injections, although no issues have been reported when used as intended, highlighting the risks associated with improper use of the product.
- Collaboration with FDA: Neogen is proactively working with the FDA to investigate the issue and is notifying distributors and customers to ensure a smooth recall process, aiming to mitigate potential legal and financial risks.
- Customer Support: The company is providing a customer support hotline to assist with recall procedures, demonstrating its commitment to customer safety, which may also impact future sales and market trust.
- Product Recall: Neogen Corporation is voluntarily recalling all lots of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution due to microbial contamination found in certain batches, involving both 2mL/20mg and 10mL/50mg vials, demonstrating the company's commitment to product safety.
- Adverse Event Reports: Following intraarticular injections in horses, Neogen received multiple reports of adverse events, although no issues were reported when used as intended, indicating potential serious consequences from improper use that could impact the company's reputation.
- Collaboration with FDA: Neogen is proactively working with the FDA on this recall and is notifying distributors and direct customers via email to ensure the safe return of all recalled products, reflecting the company's commitment to compliance and safety.
- Customer Support: The company provides detailed recall information and support channels, including phone and email, ensuring customers can smoothly return products and address related issues, highlighting Neogen's focus on customer service.










